Sofinnova Partners is an independent venture capital firm based in Paris, France. For more than 40 years, the firm has backed nearly 500 companies at different stages of their development – pure creations, spin-offs, as well as turnaround situations – and worked alongside Europe’s key entrepreneurs in the Life Sciences industry. With €1.3 billion of funds under management, Sofinnova Partners has created market leaders with its experienced team and hands-on approach in building portfolio companies through to exit.
Imperial Innovations creates, builds and invests in pioneering technologies addressing global problems in healthcare, energy, engineering and the environment. It combines deep understanding of science and technology with commercial acumen and strong investment expertise, and supports scientist-entrepreneurs in the commercialisation of their ideas. In December 2010 Innovations raised £140 million to accelerate the making of, and increase the size of, investments in companies established under its existing intellectual property pipeline agreement with Imperial College London. The Group also invests in companies founded by or based on technology from the University of Oxford, the University of Cambridge and University College London.
Astellas Venture Management LLC. is the corporate venture capital arm of Astellas Pharma Inc., a global pharmaceutical company headquartered in Tokyo, Japan, which was formed through the merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. in April 2005. AVM’s investment objective is to find a venture company with a proprietary technology and facilitate its growth by utilising Astellas’ experience and network within the biotechnology field. AVM’s ability to offer not only investment funds, but also the Astellas Group’s powerful combination of scientific and technical expertise, depth of drug development and marketing knowledge and long-term business perspective, can give entrepreneurs and investors the very best chance for their rapid growth and success.
EMBL Ventures is an independent venture capital investor that manages two Funds with a total of €68 million capital on behalf of major European institutional and private investors. EMBL Ventures originates companies and supplies financing for the development of next generation technologies. Based on this approach, six of sixteen portfolio companies have generated to date a transaction volume of more than € 1.5 billion in risk sharing deals with Pharma partners. EMBL Ventures' close relationship with the European Molecular Biology Laboratory (EMBL) and its technology transfer organization EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) allows it to finance disruptive technologies in an entrepreneurial start-up environment, aiming ultimately for a transaction with a partner that is seeking to acquire external product innovation. EMBL Ventures is exclusively focused on life-science investments.
Babraham Commercialisation Services Limited is the wholly-owned trading arm of the Babraham Institute. The Babraham Institute undertakes innovative life-sciences research to discover the molecular mechanisms that underlie normal cellular processes and functions, with the aim of improving lifelong wellbeing and healthy ageing. The Institute aims to maximise the impact of its research through knowledge exchange and commercialisation, and its scientists work with other organisations to translate that research into action for social and economic benefit. Babraham Commercialisation Services supports the delivery of the commercialisation of the Babraham Institute's science. As part of this role, it manages, develops and commercialises the Babraham Institute's intellectual property portfolio. It also facilitates collaborations between the Institute and industry, and arranges access to the Institute's expertise and scientific facilities and services.
Avlar is a specialist biotechnology venture capital company and is the manager of Avlar BioVentures Fund I, Avlar BioVentures Fund II and The Cambridge Gateway Fund. All three funds are focused on seed and early stage investments and are used to invest in emerging bioscience technologies. Avlar's approach to investment is very much 'hands on', working intensively with companies in the critical stages of development from pre-formation to second round of financing, applying its strategic, entrepreneurial and biotech industry skills.
The £10m Rainbow Seed Fund was established in 2002 with funding from the Office of Science and Innovation to commercialise scientific research in a leading group of the UK publicly funded institutions, our partners. The Fund, which is independently managed by Midven Ltd, made its first investment in 2002, and currently has a portfolio of over 20 companies which have raised over £77,000,000 of third party capital.
The Fund invests at the earliest stages of a technology’s development, and helps to turn an idea into a business by actively identifying and supporting experienced management and facilitating additional co-investment. Rainbow's partners spend over £1 billion on research and development every year giving the Fund privileged access to high quality investment propositions at the earliest stage.